Business Context and Reporting Period
This Form 8-K was filed by Stereotaxis, Inc. on December 16, 2005. The report discloses a regulatory milestone under Item 7.01 (Regulation FD Disclosure) regarding the company's strategic alliance with Biosense Webster, Inc., a Johnson & Johnson company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory approval event and contains no financial statements or quantitative financial data.
Material Changes
The primary material event is the U.S. Food and Drug Administration (FDA) approval of the Celsius® RMT Diagnostic/Ablation Deflectable Tip Catheter. This catheter is designed to integrate with Stereotaxis's Niobe® Magnetic Navigation System. This approval marks the first ablation catheter to be commercialized in the U.S. under the strategic alliance between Stereotaxis and Biosense Webster.
Outlook and Management Commentary
- Strategic Impact: The FDA approval provides electrophysiologists in the U.S. with enhanced maneuvering capabilities when using the Niobe® system for cardiac ablation procedures.
- Global Status: The Celsius® RMT ablation catheter previously received CE Marking Authorization for commercialization in Europe in March 2005.
- Regulatory Note: The information is furnished pursuant to Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the commercial launch timeline for the Celsius® RMT catheter in the U.S. market.
- Assess the potential revenue impact of the strategic alliance with Biosense Webster on future quarters.
- Confirm the integration status of the new catheter with the existing Niobe® Magnetic Navigation System inventory.
- Review subsequent filings for any updates on adoption rates by U.S. electrophysiologists.